Happier future for older drugs
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.DRUGMAKERS ARE seeking to breathe new life into older antidepressants with new studies that show their drugs can treat depression just as well as the newer ones - and allow patients to enjoy a better sex life.
Glaxo Wellcome and Bristol-Myers Squibb, which ranks fourth, presented two separate studies to a conference in Paris at the weekend showing patients taking Wellbutrin and Serzone are more likely to go on having a normal sex life than those taking newer antidepressants such as Eli Lilly's Prozac, SmithKline Beecham's Paxil, Pfizer's Zoloft and Akzo Nobel's Remeron.
The studies, presented at the 11th European Congress of Neuropsychopharmacology
could help convince some of the attending 6,000 doctors to prescribe the drugs, especially if it means their patients are more likely to stick with the treatment, analysts said.
New treatments have been threatening to eclipse the older generation of medicines and cut their share of the $8.4bn worldwide market for depression drugs dramatically. Prozac and other drugs of a class called selective serotonin reuptake inhibitors, or SSRIs, have allowed many depressed patients to lead normal lives. Like most powerful treatments, however, they're not free of side effects.
"The problem of the SSRIs is that they cause impotence,'' Mark Becker, an analyst at JP Morgan Securities, said before the conference opened.
Drugmakers that can show their products have fewer such consequences and are at the same time effective at treating depressions could gain market share, Becker said.
One study, paid for by Glaxo, shows depressed patients taking Wellbutrin stand a better chance of keeping a normal sex life than those taking Zoloft.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments